Trofinetide
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Trofinetide
- Accession Number
- DB06045
- Description
Trofinetide (NNZ-2566), a neuroprotective analogue of glypromate, is a novel molecule that has a profile suitable for both intravenous infusion and chronic oral delivery. It is currently in development to treat traumatic brain injury.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Trofinetide (DB06045)
- Weight
- Average: 315.326
Monoisotopic: 315.143035408 - Chemical Formula
- C13H21N3O6
- Synonyms
- Trofinetide
- External IDs
- NNZ 2566
- NNZ-2566
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Investigated for use/treatment in traumatic brain injuries.
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
NNZ-2566 is shown to have multi-faceted action to significantly reduce both inflammation and apoptosis (cell death), protecting the neurons and their surrounding infrastructure.
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Glutamic acid and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Pyrrolidinecarboxamides / N-acylpyrrolidines / Heterocyclic fatty acids / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Amino acids show 6 more
- Substituents
- Aliphatic heteromonocyclic compound / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid / Amino acid or derivatives / Azacycle / Carbonyl group / Carboxamide group show 24 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- Z2ME8F52QL
- CAS number
- 853400-76-7
- InChI Key
- BUSXWGRAOZQTEY-SDBXPKJASA-N
- InChI
- InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1
- IUPAC Name
- (2S)-2-{[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidin-2-yl]formamido}pentanedioic acid
- SMILES
- C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 9493869
- ChEMBL
- CHEMBL197084
- Wikipedia
- Trofinetide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Enrolling by Invitation Treatment Rett's Syndrome 2 3 Recruiting Treatment Rett's Syndrome 1 2 Completed Supportive Care Injuries, Brain 1 2 Completed Treatment Fragile X Syndrome (FXS) 1 2 Completed Treatment Injuries, Brain 1 2 Completed Treatment Rett's Syndrome 2 2 Terminated Treatment Concussions 1 1 Completed Treatment Brain Injuries,Traumatic 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 10.4 mg/mL ALOGPS logP -3 ALOGPS logP -4.5 ChemAxon logS -1.5 ALOGPS pKa (Strongest Acidic) 3.27 ChemAxon pKa (Strongest Basic) 7.83 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 150.03 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 73.79 m3·mol-1 ChemAxon Polarizability 30.95 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on November 18, 2007 18:29 / Updated on February 21, 2021 18:51